Expression of Recombinant CTLA-۴ and PD-L۱ Proteins Fused with Thioredoxin, and Determination of Their Ligand-Binding Activities

سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 239

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RBMB-11-2_014

تاریخ نمایه سازی: 21 مرداد 1401

چکیده مقاله:

Background: The use of chimeric proteins that selectively interact with various immune cell receptors to treat oncology patients has increased. One effective way to obtain recombinant proteins is to use the E. coli expression system. However, in eukaryotic protein production in E. coli, several difficulties arise that can be solved by fusing the target protein with thioredoxin. Thioredoxin can enhance solubility, but its large size can lead to an erroneous assessment of protein solubility, folding, and activity. The present study examined the ligand-binding activity of PD-L۱, and CTLA-۴ receptors fused with thioredoxin. Methods: The de novo synthesized genes of the extracellular domains of the PD-L۱ and CTLA-۴ were cloned into the pET۲۸ and pET۳۲ expression plasmids and used to transform E. coli BL۲۱ cells. Purified recombinant proteins were characterized by western blotting, LC-MS/MS spectrometry, and ELISA. Results: Amino acid sequence comparisons of the recombinant proteins obtained by LC-MS/MS with the SwissProt database resulted in the highest comparison scores from ۴۹۵۰ to ۱۳۳۹۶. The binding efficiencies of recombinant human B۷-۱ Fc to rCTLA-۴ and rTrx-CTLA-۴ proteins in ELISA did not differ significantly. Similar results were obtained with recombinant rhesus monkey PD-۱ hFc against rPD-L۱ and rTrx-PD-L۱. Conclusions: Recombinant proteins specifically reacted with recombinant human B۷-۱ Fc and recombinant rhesus monkey PD-۱ hFc. The fusion of thioredoxin with recombinant proteins through linkers slightly affected the activity of the extracellular domains of CTLA-۴ and PD-L۱.

نویسندگان

Adish Zhansaya

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan & L. N. Gumilyov Eurasian National University, Satpayev st., ۲, Nur-Sultan, ۰۱۰۰۰۸, Kazakhstan.

Nurtleu Malika

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan & L. N. Gumilyov Eurasian National University, Satpayev st., ۲, Nur-Sultan, ۰۱۰۰۰۸, Kazakhstan.

Dzantiev Boris

A. N. Bach Institute of Biochemistry, Russian Academy of Sciences, Leninsky Prospect ۳۳, Moscow, ۱۱۹۰۷۱, Russian Federation.

Tursunov Kanat

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan.

Mukantayev Kanatbek

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan.

Ramankulov Yerlan

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan.

Mukanov Kasym

National Center for Biotechnology, Kurgalzhyn road, ۱۳/۵, Nur-Sultan, ۰۱۰۰۰۰, Kazakhstan.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Jiawen C, Steven CA, Yinghao W. General principles of binding ...
  • Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy Comes of ...
  • Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, ...
  • Hosseinzadeh F, Mohammadi S, Nejatollahi F. Production and Evaluation of ...
  • Buchbinder EI, Anupam D. CTLA-۴ and PD-۱ pathways similarities, differences, ...
  • Shen X, Zhao B. Efficacy of PD-۱ or PD-L۱ inhibitors ...
  • Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, ...
  • Sepahi S, Pasdar A, Gerayli S, Rostami S, Gholoobi A, ...
  • Seror R, Mariette X. Malignancy and the risks of biologic ...
  • Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, ...
  • Peraino J, Huiping Z, Hermanrud CE, Guoying L, Sachs DH, ...
  • Cox GN, Pratt D, Smith D, McDermott MJ, Vanderslice RW. ...
  • Kalim M, Jie C, Shenghao W, Caiyao L, Saif U, ...
  • Sezonov G, Danièle JP, Richard DA. Escherichia coli physiology in ...
  • Hartley JL. Cloning technologies for protein expression and purification. Curr ...
  • Jana S, Deb JK. Strategies for efficient production of heterologous ...
  • Kumar JK, Stanley T, Richardson CC. Proteomic analysis of thioredoxin-targeted ...
  • Zhenyu G, Weidenhaupt M, Ivanova N. et al. Chromatographic methods ...
  • Xu L, Liu Y, He X. Expression and purification of ...
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. ...
  • Keir ME, Manish JB, Freeman GJ, Sharpe AH. PD-۱ and ...
  • Joel S, Taube JM. PD-۱/PD-L۱ inhibitors. Curr Opin Pharmacol. ۲۰۱۵;۲۳:۳۲-۸ ...
  • Arun R, Gulley JL. Nivolumab (anti-PD-۱, BMS-۹۳۶۵۵۸, ONO-۴۵۳۸) in patients ...
  • Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. ...
  • Zaretsky JM, Angel GD, Shin DS, Helena EO, Willy H, ...
  • Seidel JA, Otsuka A, Kabashima K. Anti-PD-۱ and anti-CTLA-۴ Therapies ...
  • Müller D, Bayer K, Mattanovich D. Potentials and limitations of ...
  • Nazzareno D, Gao C, Fleming R, Robert MW, Yao XT, ...
  • Vallejo LF, Ursula R. Optimized procedure for renaturation of recombinant ...
  • Yoshii H, Furuta T, Yonehara T, Ito D, YY Linko, ...
  • نمایش کامل مراجع